Literature DB >> 31891939

A Comparison of the Cystotome-Assisted Prechop and Phaco-Chop Phacoemulsification Nucleotomy Techniques.

Lian-Qun Wu1, Xu Chen2, Xiao-Ling An3, Yan-Wen Zhou4, Sen Bi3.   

Abstract

BACKGROUND The aim of this study was to compare the intra-operative parameters and post-operative outcomes of cataract surgery performed using the cystotome-assisted prechop (CAP) and phaco-chop techniques. MATERIAL AND METHODS Fifty-two eyes with age-related cataract in the CAP group, and 63 eyes in the phaco-chop group were enrolled for analysis in this study, and the surgical outcomes were reported 1 day and/or 1 week, and 1 month post-operatively. RESULTS The CAP technique was associated with statistically significantly lower cumulative dissipated energy compared with the phaco-chop technique (P<0.001). The mean endothelial cell loss in the CAP group was statistically significantly lower than that of the phaco-chop group 1 week (5.6±5.9% versus 8.8±8.7%, P=0.020) and 1 month post-operatively (6.3±6.8% versus 9.8±9.9%, P=0.026). The change in the central corneal thickness between the 2 groups was significantly different at 1 day post-operatively (3.3±3.1% versus 4.9±4.6%, P=0.036). The change in the 8.0 mm central corneal volume between the 2 groups was significantly different at 1 day and 1 week post-operatively (6.5±6.1% versus 10.9±7.9%, P=0.001; 3.2±4.7% versus 5.4±5.7%, P=0.029, respectively). CONCLUSIONS The CAP technique showed lower ultrasound energy consumption and less endothelial damage and corneal edema than the phaco-chop technique. It might therefore prove a cost-effective prechop method for cataract surgery.

Entities:  

Mesh:

Year:  2019        PMID: 31891939     DOI: 10.12659/MSM.919043

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  1 in total

1.  Application of prechop technique in phacoemulsification for cataract patients with highly liquefied vitreous: a retrospective study.

Authors:  Jing Zhao; Zhouyue Li; Yu Liu; Xiaotong Han; Shengsong Huang
Journal:  BMC Ophthalmol       Date:  2022-04-14       Impact factor: 2.209

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.